IBRX•IBRX shares rose 2.61% during regular trading but slipped overnight after an insider sold shares, testing retail optimism ahead of its lead drug’s upcoming FDA review. The insider sale marks the first such transaction this quarter as investors await the decision.
IBRX shares jumped 2.61% during the regular session but dipped in premarket trading following news of the insider sale, reversing earlier gains.
A company officer executed the first insider sale of the quarter, offloading shares that have prompted investors to reassess confidence in near-term upside.
The stock movement comes as the market positions ahead of a pending FDA decision on IBRX’s lead therapy, which is expected to be a major catalyst for valuation.
